Get the Stockscreener App
14.16
2.55%
-0.37
After Hours:
14.16
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Viatris Inc stock is traded at $14.16, with a volume of 10.82M.
It is down -2.55% in the last 24 hours and down -2.88% over the past month.
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. The remaining 60% of sales are derived from its portfolio of legacy products, which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.
See More
Previous Close:
$14.53
Open:
$14.19
24h Volume:
10.82M
Relative Volume:
1.12
Market Cap:
$16.30B
Revenue:
$14.33B
Net Income/Loss:
$-3.79B
P/E Ratio:
-4.4669
EPS:
-3.17
Net Cash Flow:
$1.84B
1W Performance:
-5.16%
1M Performance:
-2.88%
6M Performance:
+34.86%
1Y Performance:
+48.90%
1-Day Range:
$13.98
$14.39
1-Week Range:
$13.98
$15.77
52-Week Range:
$6.85
$16.47
Viatris Inc Stock (VTRS) Company Profile
Name
Viatris Inc
Sector
Phone
(724) 514-1465
Address
1000 MYLAN BOULEVARD, CANONSBURG
Compare VTRS vs TAK, ZTS, HLN, TEVA, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VTRS
Viatris Inc
|
14.16 | 16.73B | 14.33B | -3.79B | 1.84B | -3.17 |
|
TAK
Takeda Pharmaceutical Co Adr
|
17.88 | 56.11B | 29.85B | 776.90M | 4.35B | 0.2408 |
|
ZTS
Zoetis Inc
|
121.43 | 51.60B | 9.47B | 2.67B | 2.28B | 6.0218 |
|
HLN
Haleon Plc Adr
|
10.28 | 46.00B | 14.54B | 2.22B | 2.58B | 0.4879 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
31.05 | 36.98B | 17.41B | 1.43B | 1.00B | 1.2182 |
|
UTHR
United Therapeutics Corp
|
478.16 | 21.26B | 3.13B | 1.27B | 1.12B | 26.39 |
Viatris Inc Stock (VTRS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-09-26 | Upgrade | UBS | Neutral → Buy |
| Jan-16-26 | Upgrade | Argus | Hold → Buy |
| Dec-09-25 | Initiated | Barclays | Overweight |
| Oct-15-25 | Initiated | Truist | Buy |
| Jun-06-25 | Initiated | Goldman | Neutral |
| Jul-19-24 | Resumed | Jefferies | Buy |
| Oct-23-23 | Downgrade | BofA Securities | Neutral → Underperform |
| Jun-23-23 | Downgrade | Barclays | Equal Weight → Underweight |
| Apr-24-23 | Downgrade | Barclays | Overweight → Equal Weight |
| Feb-17-23 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Jan-27-23 | Upgrade | Jefferies | Hold → Buy |
| Nov-10-22 | Upgrade | UBS | Sell → Neutral |
| Nov-08-22 | Upgrade | Piper Sandler | Underweight → Neutral |
| Oct-21-22 | Resumed | Jefferies | Hold |
| Jun-14-22 | Initiated | UBS | Sell |
| May-10-22 | Downgrade | Piper Sandler | Neutral → Underweight |
| Mar-01-22 | Downgrade | BofA Securities | Buy → Neutral |
| Mar-01-22 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jun-15-21 | Initiated | Citigroup | Neutral |
| Apr-07-21 | Resumed | RBC Capital Mkts | Outperform |
| Mar-08-21 | Downgrade | Goldman | Buy → Neutral |
| Mar-02-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Feb-26-21 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Jan-05-21 | Initiated | Argus | Hold |
| Dec-14-20 | Initiated | Bernstein | Mkt Perform |
View All
Viatris Inc Stock (VTRS) Latest News
Viatris Eyes Specialty Shift As FDA Reviews MR-141 Presbyopia Drug - Yahoo Finance
Goldman Sachs Adjusts Price Target on Viatris to $14 From $13, Maintains Neutral Rating - marketscreener.com
Better Value & Growth: LLY, JNJ Top Viatris Stock - Trefis
Ex-Dividend Reminder: Alphabet, Constellation Energy and Viatris - Nasdaq
Viatris Stock Hits Day Low of $15.14 Amid Price Pressure - Markets Mojo
FDA Review Of MR-141 Puts Viatris Ophthalmic Growth Story In Focus - simplywall.st
Viatris (VTRS) is a Top-Ranked Value Stock: Should You Buy? - Nasdaq
Viatris Unit Can't Ax Patent For Anemia Drug Evrenzo - Law360
Generic Pharma Q4 2025 Earnings Review: Revenue Beat, Stock DeclineNews and StatisticsIndexBox - IndexBox - Market Intelligence Platform
Viatris Inc. stock falls Tuesday, underperforms market - MarketWatch
Viatris (VTRS): From Debt-Laden Merger to Specialty Powerhouse—A 2026 Research Deep Dive - FinancialContent
VTRS Financials: Income Statement, Balance Sheet & Cash Flow | Viatris Inc Ord Shs - Stock Titan
A Look At Viatris (VTRS) Valuation After Earnings, 2026 Guidance And MR-141 FDA Review - simplywall.st
Viatris (VTRS) Delivers Solid 2025 Growth and Robust Cash Flow at Deep Value - Insider Monkey
Viatris Inc. stock rises Monday, outperforms market - MarketWatch
Viatris Inc. (VTRS) Stock Report: Navigating the Healthcare Giant’s 3.22% Dividend Yield and Revenue Growth - DirectorsTalk Interviews
Spotting Winners: Viatris (NASDAQ:VTRS) And Generic Pharmaceuticals Stocks In Q4 - Finviz
Viatris Earnings Call Highlights Slow Growth, Cash Strength - TipRanks
UBS Raises Viatris (VTRS) Price Target as Cost Savings and Growth Outlook Improve - Insider Monkey
UBS raises Viatris stock price target to $20 on cost savings - Investing.com India
Rx Rundown: Gilead Sciences, Viatris, Generate Biomedicines and more - Medical Marketing and Media
UBS Adjusts Viatris Price Target to $20 From $18, Maintains Buy Rating - marketscreener.com
Viatris Inc. (NASDAQ:VTRS) Q4 2025 Earnings Call Transcript - Insider Monkey
Viatris Inc. (VTRS) FDA Accepts sNDA for Presbyopia Treatment with October PDUFA Date - Finviz
JPMorgan Adjusts Price Target on Viatris to $17 From $16, Maintains Neutral Rating - marketscreener.com
A Look At Viatris (VTRS) Valuation After Earnings Beat And 2026 Guidance Update - Yahoo Finance
Viatris (VTRS) Quarterly Loss Of US$340.1 Million Tests Profitability Turnaround Narrative - Sahm
Decoding Viatris Inc (VTRS): A Strategic SWOT Insight - GuruFocus
Viatris Earnings: Drugmaker Left 2025 With Momentum; 2026 to Bring Stability and Broad-Based Growth - Morningstar
Viatris: Q4 Earnings Snapshot - theheraldreview.com
BofA raises Viatris stock price target on cost-cutting plan - Investing.com
Viatris Inc. stock falls Thursday, underperforms market - MarketWatch
Is Strong Q4 Revenue And Steady Dividend Policy Altering The Investment Case For Viatris (VTRS)? - simplywall.st
Viatris Looks Well-Positioned for Durable Growth From New Launches and Cost Savings Initiatives - Morningstar
Viatris Q4 EPS Tops, Brands Drive Revenue Growth, Stock Up - Finviz
Earnings call transcript: Viatris Q4 2025 earnings beat forecasts, stock up - Investing.com
Viatris Q4 2025 slides: earnings beat, major cost-cutting plan - Investing.com
Viatris Q4 2025 slides: earnings beat, major cost-cutting plan By Investing.com - Investing.com South Africa
Restructuring: Viatris to cut global workforce by about 10% - Pittsburgh Post-Gazette
Viatris Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 - marketscreener.com
Viatris (NASDAQ:VTRS) Posts Better-Than-Expected Sales In Q4 CY2025 - The Globe and Mail
The Pivot to Growth: Viatris (VTRS) Enters Phase 2 with 2026 Dividend and Capital Allocation Strategy - FinancialContent
Viatris (VTRS) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates - Yahoo Finance
Viatris (VTRS) Surpasses Q4 Earnings and Revenue Estimates - Yahoo Finance
Viatris Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Viatris Inc. 2025 Q4ResultsEarnings Call Presentation (NASDAQ:VTRS) 2026-02-26 - Seeking Alpha
Viatris forecasts 2026 profit below estimates on India manufacturing woes - marketscreener.com
Viatris Launches Major Restructuring After Strong 2025 Results - TipRanks
Viatris maintains annual dividend at 48 cents for 2026 - Investing.com
Viatris Inc. Announces Quarterly Dividend, Payable on March 18, 2026 - marketscreener.com
Viatris Inc. Provides Earnings Guidance for the Fiscal Year 2026 - marketscreener.com
Viatris Inc Stock (VTRS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Viatris Inc Stock (VTRS) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Le Goff Corinne | Chief Commercial Officer |
Mar 04 '26 |
Option Exercise |
0.00 |
39,773 |
0 |
72,019 |
| Enrietti Andrew | See Remarks |
Mar 03 '26 |
Option Exercise |
0.00 |
110,630 |
0 |
248,032 |
| Campbell Paul | See Remarks |
Mar 04 '26 |
Option Exercise |
0.00 |
18,720 |
0 |
377,939 |
| Campbell Paul | See Remarks |
Mar 03 '26 |
Option Exercise |
0.00 |
190,027 |
0 |
435,151 |
| Smith Scott Andrew | Chief Executive Officer |
Mar 04 '26 |
Option Exercise |
0.00 |
101,217 |
0 |
1,281,172 |
| Smith Scott Andrew | Chief Executive Officer |
Mar 03 '26 |
Option Exercise |
0.00 |
1,440,831 |
0 |
1,695,045 |
| Mistras Theodora | Chief Financial Officer |
Jan 01 '26 |
Option Exercise |
0.00 |
25,260 |
0 |
48,265 |
| Le Goff Corinne | Chief Commercial Officer |
Sep 11 '25 |
Sale |
10.25 |
7,032 |
72,045 |
35,299 |
1.16%
0.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):